| Literature DB >> 24391802 |
Solimabi Wahidullah1, Deepak N Naik1, Prabha Devi1.
Abstract
As part of a proactive approach to environmental protection, emerging issues with potential impact on the environment is the subject of ongoing investigation. One emerging area of environmental research concerns pharmaceuticals like salicylic acid, which is the main metabolite of various analgesics including aspirin. It is a common component of sewage effluent and also an intermediate in the degradation pathway of various aromatic compounds which are introduced in the marine environment as pollutants. In this study, biotransformation products of salicylic acid by seaweed, Bryopsis plumosa, associated marine bacterium, Moraxella spp. MB1, have been investigated. Phenol, conjugates of phenol and hydroxy cinnamic acid derivatives (coumaroyl, caffeoyl, feruloyl and trihydroxy cinnamyl) with salicylic acid (3-8) were identified as the bioconversion products by electrospray ionization mass spectrometry. These results show that the microorganism do not degrade phenolic acid but catalyses oxygen dependent transformations without ring cleavage. The degradation of salicylic acid is known to proceed either via gentisic acid pathway or catechol pathway but this is the first report of biotransformation of salicylic acid into cinnamates, without ring cleavage. Besides cinnamic acid derivatives (9-12), metabolites produced by the bacterium include antimicrobial indole (13) and β-carbolines, norharman (14), harman (15) and methyl derivative (16), which are beneficial to the host and the environment.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24391802 PMCID: PMC3877071 DOI: 10.1371/journal.pone.0083647
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 11H NMR spectra of control salicylic acid (A) and its bioconversion products (B).
Figure 2Negative ESI-MS profile of products of fermentation of Moraxella spp. MB1 in aqueous medium without salicylic acid (A).
Positive ESI-MS profile of products of fermentation of Moraxella spp. MB1 without salicylic acid in biphasic medium (B). Positive ESI-MS profile of bioconversion products of salicylic acid (C).
Figure 3Negative ESI-MS profile of bioconversion products in methanol (A).
Negative ESI-MS profile of bioconversion products in methanol+1% formic acid (B). Positive ESI-MS profile of ethyl acetate extract of symbiont Bryopsis plumosa (C).
Figure 4Structure of bioconversion products of salicylic acid by Moraxella spp. MB1 (A).
Structure of fermentation products of seaweed associated Moraxella spp. MB1(B).
Figure 5Proposed diagnostic mass spectral fragmentation of hydroxyl cinnamic acid esters.
ESI-MS/MS in positive ionization mode (A); ESI-MS/MS in negative ionization mode (B).
Figure 6Scheme-1-Proposed metabolic pathway of formation of salicylic acid conjugates with hydroxycinnamic acid derivatives by Moraxella sp. MB1.
ESI-MS/MS characterization of metabolites in Ethyl Acetate extract of fermentation of Moraxella sp. MB1in biphasic medium containing SA: A-conjugates of SA with phenol and hydroxy cinnamic acids; B- Hydroxycinnamic acids derivatives produced by the bacterium; C-Standard Phenolic acids.
| Compound identification | MW | MS (m/z) | MS2 fragmentation observed (m/z) |
| A: Conjugates | |||
| SA (1) | 138 | 137[M−H]− | 93[Phenolate]− |
| Phenol (2) | 94 | 93[M−H] | 75[Phenyl]− |
|
| 284 | 283[M−H]− | 163 [Coumaratel]− |
| P-tri-OHCi (4) | 272 | 273[M+H]+ | 179 [Trihydroxy cinnamoyl]+; 161 [Trihydroxy cinnamoyl – H2O]+; 143 [Trihydroxy cinnamoyl - 2H2O] +; 197[Trihydroxy cinnamic acid +H] +; 237 [M+H−2H2O] +; 219[M+H−3H2O] + |
| 2-CBA (5) | 300 | 301[M+H]+ | 283[M+H−H2O]+; 257[M+H−CO2]+; 239[M+H−(H2O+CO2)]+163[Caffeoyl] +; 181[Caffeic acid+H]+ |
| 2-FBA (6) | 314 | 315[M+H]+ | 177[Feruloyl]+; 195[Ferulic acid+H]+; 133[Ferulic acid+H−H2O−CO2]+; 297[M+H−H2O]+; 253[M+H−H2O−CO2]+ |
| 2-Tri-OH-CiBA (7) | 316 | 317[M+H]+ | 179[Trihydroxy cinnamoyl]+; 197[Trihydroxy cinnamic acid +Hl]+; 299[M+H−H2O] +; 271[M+H−HCOOH] +; 219[M+H−3H2O−CO2] + |
| p-CoBA MeEt (8) | 298 | 299[M+H]+ | 281[M+H−H2O]+; 267[M+H−CH3OH]+; 255[M+H−CO2]+; 237[M+H−(H2O+CO2)]+; 219[M+H−(2H2O+CO2)]+161[p-methoxy cinnamoyl]+ |
| B. Hydroxycinnamic acids derivatives | |||
| p-Co-MeEt (9) | 178 | 179[M+H]+ | 161[p-methoxycinnamoyl]+; 143[p-methoxycinnamoyl-H2O] +; 135[M+H−CO2]+; 133[M+H−HCOOH]+;103[M+H−(CH3OH+CO2)]+ |
| p-MeEt of Co-MeEs (10) | 192 | 193[M+H]+ | 161[p-methoxycinnamoyl]+; 149[M+H−CO2]+;143[M+H−(CH3OH+H2O)]+; 133[M+H−(HCOOCH3)] +;103[M+H−(OCH3+COOCH3)] + |
| Methyl caffeate (11) | 194 | 195[M+H]+ | 181[M+H−CH3] +;177[M+H−H2O] +;163[caffeoyl]+;151[M+H−CO2] +; 149[M+H−HCOOH] +;133[M+H−(H2O+CO2)]+ |
| p-OH-styrene (12) | 120 | 121[M+H]+ | 103[M+H−H2O]+; 93[Phenolate]+ |
| C. Standard hydroxy CA | |||
| Cinnamic acid | 148 | 149[M+H]+ | 121[M+H−CO]+; 103[M+H−HCOOH]+; 77 [C6H5]+; 65[C5H5] |
| p-Coumaric acid | 164 | 165[M+H]+ | 147[p-hydroxy cinnamoyl]+; 119[M+H−HCOOH]+; 77[C6H5]+ |
| p-OMe-CA | 178 | 179 [M+H]+ | 161[M+H−H2O]+;133[M+H−HCOOH]+;77[C6H5]+; 118[M+H−(HCOOH+CH3)]+;109[M+H−SC]+; 103[M+H−(CO2+OCH3]+ |
| Caffeic acid | 180 | 179[M−H]− | 135[M−H− CO2]−; 89 [M−H−(CO2+HCOOH]− |
| Ferulic acid | 194 | 193[M−H]− | 178[M−H−CH3]−; 149[M−H−CO2]_; 134[M−H−(CO2+CH3)]− |
SA, salicylic acid; P-phenol; p-CoBA, para-coumaroylbenzoic acid; P-tri-OHCi, phenyltrihydroxycinnamate; 2-CBA, 2-caffeoyl benzoic acid; 2-FBA, 2- feruloylbenzoic acid; 2-Tri-OH-CiBA, 2-trihydroycinnamoylbenzoic acid; p-CoBA MeEt, para -coumaroylbenzoic acid methyl ether; p-Co-MeEt, para-coumaric acid methyl ether; p-MeEt of Co-MeEs, para-methy ether of methylcoumarate; p-OMe-CA, para-methoxycinnamic acid.